<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<button type="button" class="collapsible">yosi - dana_a</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  As single agents ,  <span class="marker" data-anno-id="0" data-anno-label="P1">curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">metformin</span>  are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h4>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P ≤ 0.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4 mm</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  There was no cytotoxic effect of  <span class="marker" data-anno-id="0" data-anno-label="N1">cisplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="N1">ifosfamide</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="N1">etoposide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h4>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="0" data-anno-label="P1">mycophenolate</span>  mofetil and intravenous  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Dual antiplatelet therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">clopidogrel</span>  ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h4>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="C1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="C1">tobramycin</span>  were administered hourly . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h4>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="P1">cisplatin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="P1">paclitaxel</span>  , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">enzalutamide</span>  , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent trends in the management of advanced prostate cancer.</u></h4>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.</div></div></div></div><button type="button" class="collapsible">yosi - yuval</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C2/C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C2/C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C2">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  mofetil and intravenous  <span class="marker" data-anno-id="2" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent trends in the management of advanced prostate cancer.</u></h4>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase ,  <span class="marker" data-anno-id="0" data-anno-label="C1">tetrahydroaminoacridine</span>  ( i.p . ) , and a glycine-B site partial agonist ,  <span class="marker" data-anno-id="1" data-anno-label="C1">D-cycloserine</span>  ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.</div></div></div></div><button type="button" class="collapsible">yosi - dana_n</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  There was no cytotoxic effect of  <span class="marker" data-anno-id="0" data-anno-label="C1">cisplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">ifosfamide</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">etoposide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h4>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="P2/C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2/P1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1/P1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  He was initially treated with combination chemotherapy regimen of  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">actinomycin-D</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  ( VAC therapy ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  He was initially treated with combination chemotherapy regimen of  <span class="marker" data-anno-id="0" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">actinomycin-D</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">cyclophosphamide</span>  ( VAC therapy ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h4>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="0" data-anno-label="P1">mycophenolate</span>  mofetil and intravenous  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="C1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="C1">tobramycin</span>  were administered hourly . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="P1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="P1">tobramycin</span>  were administered hourly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h4>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Additivity , synergy , or competition was observed with MIS and  <span class="marker" data-anno-id="0" data-anno-label="P1">rapamycin</span>  , AzadC ,  <span class="marker" data-anno-id="1" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cisplatin</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P1">paclitaxel</span>  , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase ,  <span class="marker" data-anno-id="0" data-anno-label="P1">tetrahydroaminoacridine</span>  ( i.p . ) , and a glycine-B site partial agonist ,  <span class="marker" data-anno-id="1" data-anno-label="P1">D-cycloserine</span>  ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">adriamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">vincristine</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C1">prednisolone</span>  every three months . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">adriamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">vincristine</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P1">prednisolone</span>  every three months . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h4>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.</div></div></div></div><button type="button" class="collapsible">yosi - hagit</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  As single agents ,  <span class="marker" data-anno-id="0" data-anno-label="C1">curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">metformin</span>  are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h4>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P ≤ 0.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4 mm</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  There was no cytotoxic effect of  <span class="marker" data-anno-id="0" data-anno-label="C1">cisplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">ifosfamide</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">etoposide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h4>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ( CTX ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">mitoxantrone</span>  ( MXT ) , with dose escalation of  <span class="marker" data-anno-id="2" data-anno-label="C1">paclitaxel</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclophosphamide</span>  ( CTX ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">mitoxantrone</span>  ( MXT ) , with dose escalation of  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h4>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="P1">cisplatin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="P1">paclitaxel</span>  , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent trends in the management of advanced prostate cancer.</u></h4>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  The present study examined the efficacy of single and combined treatment with an  <span class="marker" data-anno-id="0" data-anno-label="C1">anticholinesterase</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">tetrahydroaminoacridine</span>  ( i.p . ) , and a glycine-B site partial agonist ,  <span class="marker" data-anno-id="2" data-anno-label="C1">D-cycloserine</span>  ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.</div></div></div></div><button type="button" class="collapsible">yosi - maytal</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  As single agents ,  <span class="marker" data-anno-id="0" data-anno-label="P1">curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">metformin</span>  are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h4>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P ≤ 0.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4 mm</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C3/C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C3/C2">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1/C2">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="0" data-anno-label="P1">mycophenolate</span>  mofetil and intravenous  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Combination treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">cetuximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">nystatin</span>  selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Combination treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">cetuximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">nystatin</span>  selectively increased  <span class="marker" data-anno-id="2" data-anno-label="P1">cetuximab</span>  uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h4>Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nystatin-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="C1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="C1">tobramycin</span>  were administered hourly . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="P1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="P1">tobramycin</span>  were administered hourly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h4>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2/P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with  <span class="marker" data-anno-id="2" data-anno-label="P2">autologous hematopoietic stem cell transplantation</span>  ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase ,  <span class="marker" data-anno-id="0" data-anno-label="C1">tetrahydroaminoacridine</span>  ( i.p . ) , and a glycine-B site partial agonist ,  <span class="marker" data-anno-id="1" data-anno-label="C1">D-cycloserine</span>  ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.</div></div></div></div><button type="button" class="collapsible">yosi - yakir</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  As single agents ,  <span class="marker" data-anno-id="0" data-anno-label="P1">curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">metformin</span>  are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.</u></h4>Effective chemoprevention is critical for improving outcomes of oral cancer. <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exhibit</i></b> <b style='color:DodgerBlue;'><i>chemopreventive</i></b> <b style='color:DodgerBlue;'><i>properties</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P ≤ 0.0001). Chemopreventive treatment of the animals at 17th week with <b style='color:Tomato;'><i>curcumin</i></b> and <b style='color:Tomato;'><i>metformin</i></b> indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4 mm</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  There was no cytotoxic effect of  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">cisplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">ifosfamide</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P2">etoposide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.</u></h4>The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. <b style='color:DodgerBlue;'><i>There</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and  <span class="marker" data-anno-id="0" data-anno-label="P2">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="1" data-anno-label="P2">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="0" data-anno-label="P1">mycophenolate</span>  mofetil and intravenous  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  , AzadC ,  <span class="marker" data-anno-id="2" data-anno-label="P2">doxorubicin</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">cisplatin</span>  , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  The present study examined the efficacy of single and combined treatment with an anticholinesterase ,  <span class="marker" data-anno-id="0" data-anno-label="P2">tetrahydroaminoacridine</span>  ( i.p . ) , and a glycine-B site partial agonist ,  <span class="marker" data-anno-id="1" data-anno-label="P2">D-cycloserine</span>  ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticholinesterase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tetrahydroaminoacridine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>glycine-B</i></b> <b style='color:DodgerBlue;'><i>site</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>agonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>D-cycloserine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.p</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>allosteric</i></b> <b style='color:DodgerBlue;'><i>modulator</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>NMDA</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>alleviating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>deficit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>maze</i></b> <b style='color:DodgerBlue;'><i>spatial</i></b> <b style='color:DodgerBlue;'><i>navigation</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrolytic</i></b> <b style='color:DodgerBlue;'><i>lesion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>medial</i></b> <b style='color:DodgerBlue;'><i>septum</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsal</i></b> <b style='color:DodgerBlue;'><i>hippocampi</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal <b style='color:Tomato;'><i>lidocaine</i></b> infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect.</div></div></div></div><button type="button" class="collapsible">yosi - shaked</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  , but also on other modifications and the advisability of adding  <span class="marker" data-anno-id="1" data-anno-label="C1">bevacizumab</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h4>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  He was initially treated with combination chemotherapy regimen of  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">actinomycin-D</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  ( VAC therapy ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h4>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P3/P2">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Dual antiplatelet therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">clopidogrel</span>  ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h4>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ( CTX ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">mitoxantrone</span>  ( MXT ) , with dose escalation of  <span class="marker" data-anno-id="2" data-anno-label="C1">paclitaxel</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h4>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Combination treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">cetuximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">nystatin</span>  selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h4>Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nystatin-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="C1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="C1">tobramycin</span>  were administered hourly . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h4>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent trends in the management of advanced prostate cancer.</u></h4>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">adriamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">vincristine</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C1">prednisolone</span>  every three months . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h4>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.</div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }
</script>
</body>

</html>